5-Amino-1MQ

Overview

5-Amino-1MQ targets one of the most overlooked enzymes in metabolic biology — nicotinamide N-methyltransferase, or NNMT — and blocks it. That single action has downstream effects on fat cell metabolism, NAD⁺ availability, and potentially on aging-related cellular decline. It's a small molecule, taken orally, and it's generated real interest in the longevity and metabolic research communities. The catch: every meaningful result so far has come from animal studies. No completed human clinical trials exist.

The compound's full name is 5-amino-1-methylquinolinium. It was developed specifically to probe what happens when you remove NNMT's brake on the NAD⁺ salvage pathway — and the preclinical data has been compelling enough that it's found its way into the gray-market research chemical space. Whether that translates to humans the way the mouse data suggests is still genuinely unknown.

If you're looking at this page because you're considering using it, or because a clinic has mentioned it, the most important thing to understand upfront is where the evidence actually stands: preclinical, not clinical. That doesn't mean it's without promise. It means the human chapter hasn't been written yet.

Mechanism of Action

Selective inhibition of nicotinamide N-methyltransferase (NNMT); enhances NAD⁺ salvage pathway flux

The story starts with NAD⁺ — nicotinamide adenine dinucleotide — which your cells use to power hundreds of metabolic reactions, including the ones that determine how efficiently you burn fat and how well your mitochondria function. NAD⁺ levels decline with age, and that decline is linked to slower metabolism, reduced cellular repair capacity, and accumulating fat mass. Most NAD⁺-boosting strategies you've probably heard of — NMN, NR — work by adding precursors upstream. 5-Amino-1MQ works differently. It removes a drain.

NNMT is an enzyme expressed heavily in adipose (fat) tissue. Its job is to methylate nicotinamide — essentially consuming the raw material that would otherwise be recycled into NAD⁺ through the salvage pathway. When NNMT is highly active, it diverts nicotinamide away from NAD⁺ synthesis and simultaneously burns through S-adenosylmethionine (SAM), a universal methyl donor involved in epigenetic regulation. High NNMT activity in fat tissue is associated with obesity and metabolic dysfunction.[1]

5-Amino-1MQ fits into NNMT's active site and blocks it selectively. With NNMT inhibited, nicotinamide stays in the salvage pathway and gets converted to NAD⁺ instead of being methylated and excreted. Intracellular NAD⁺ rises. SAM is preserved. The downstream effect — at least in mouse models — is that fat cells shift from storage mode toward energy expenditure, and whole-body fat mass decreases without caloric restriction.[1]

The "selective" part matters. NNMT inhibitors that aren't selective can interfere with related methyltransferases involved in DNA and histone methylation, which creates obvious safety concerns. The design goal with 5-Amino-1MQ was specificity for NNMT's active site — though how well that selectivity holds across human physiology hasn't been tested in trials.

What the Evidence Shows

Here's the honest version: the evidence is preclinical. All of it. That's not a dismissal — the preclinical data is genuinely interesting — but it's the reality you need to understand before evaluating this compound.

The most cited work comes from studies using diet-induced obese mouse models. In those experiments, NNMT inhibition with compounds in the 5-Amino-1MQ class produced meaningful reductions in fat mass, improved metabolic markers, and raised NAD⁺ levels in adipose tissue — without the animals eating less.[1] That last part is what generated excitement: fat loss without appetite suppression or caloric restriction is a different mechanism than anything currently approved.

In-vitro work has shown that NNMT inhibition in human adipocyte cell lines (fat cells grown in a lab) shifts those cells toward a more metabolically active phenotype, increasing expression of genes associated with fat oxidation.[1] That's a step closer to human relevance than a mouse study, but it's still not a human trial.

The epigenetic angle is also real. Because NNMT consumes SAM, high NNMT activity can alter methylation patterns on DNA and histones — the chemical tags that regulate which genes are expressed. In theory, inhibiting NNMT preserves SAM availability and supports normal epigenetic regulation. Whether this translates to meaningful anti-aging effects in humans is, at this point, speculation grounded in plausible biology.

No Phase 1 safety trial. No dose-finding study in humans. No randomized controlled trial of any phase. That's where things stand.

Side Effects
The honest answer is that we don't have a characterized human side effect profile for 5-Amino-1MQ. That's not a hedge — it's the clinical reality. No human trials means no systematic safety data.

What to watch for if you're using this compound: Any unexpected changes in liver enzymes, mood, or energy regulation warrant stopping and consulting a provider. Because NNMT is expressed in the liver and brain in addition to adipose tissue, effects in those tissues — positive or negative — are plausible and worth monitoring.